Novavax, Inc.
NVAX
$7.95
-$0.43-5.13%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.65% | -15.68% | -38.17% | -26.66% | -50.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.65% | -15.68% | -38.17% | -26.66% | -50.36% |
| Cost of Revenue | -45.06% | -39.19% | -54.60% | -55.16% | -51.50% |
| Gross Profit | 311.69% | 205.68% | 249.84% | 113.70% | 65.94% |
| SG&A Expenses | -29.26% | -12.59% | -6.95% | -15.44% | -6.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.47% | -29.28% | -42.40% | -45.58% | -41.54% |
| Operating Income | 57.97% | 52.62% | 53.42% | 67.62% | 14.41% |
| Income Before Tax | 67.48% | 49.22% | 50.66% | 65.67% | 16.92% |
| Income Tax Expenses | 435.89% | 367.24% | 335.94% | 10.56% | -52.68% |
| Earnings from Continuing Operations | 65.60% | 48.11% | 49.84% | 65.49% | 17.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.60% | 48.11% | 49.84% | 65.49% | 17.16% |
| EBIT | 57.97% | 52.62% | 53.42% | 67.62% | 14.41% |
| EBITDA | 64.07% | 57.66% | 58.47% | 70.63% | 17.07% |
| EPS Basic | 77.62% | 65.76% | 62.96% | 78.36% | 34.19% |
| Normalized Basic EPS | 74.18% | 66.85% | 63.27% | 79.91% | 35.96% |
| EPS Diluted | 76.09% | 64.56% | 61.93% | 77.89% | 34.16% |
| Normalized Diluted EPS | 72.55% | 65.58% | 62.22% | 79.11% | 35.68% |
| Average Basic Shares Outstanding | 51.15% | 59.44% | 54.49% | 41.56% | 28.76% |
| Average Diluted Shares Outstanding | 50.02% | 57.84% | 52.99% | 46.12% | 31.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
